Navigation Links
OncoGenex to Report Financial Results for Third Quarter 2013 and Address Key Questions from Investors on November 7, 2013
Date:10/30/2013

BOTHELL, Wash. and VANCOUVER, British Columbia, Oct. 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2013 financial results will be released on Thursday, November 7, 2013, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results and will address frequently asked questions from investors.

"For this quarter's call, we are evaluating a new format in order to address questions submitted via our website and other channels. The discussion will include recent inquiries regarding the prostate cancer market landscape and our clinical development program," stated Scott Cormack, President and CEO of OncoGenex. "While we remain blinded to the SYNERGY and Borealis-1 data, we will review the estimated timelines, which remain unchanged from those disclosed in our quarterly report on Form 10-Q for the second quarter of 2013."  

Questions can be submitted via email to investor-relations@oncogenex.com. Those received before noon Pacific/3:00 p.m. Eastern on Thursday, Nov. 7, will be considered for the discussion.

  • To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A webcast replay will be available approximately two hours after the call and will be archived on www.oncogenex.com for 90 days. You can also monitor key inf
    '/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
2. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
8. Anthera Pharmaceuticals Reports 2013 Third Quarter Financial Results, Clinical and Regulatory Update
9. Hanger Reports Third Quarter 2013 Results
10. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
11. Questcor Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 A drug commonly taken to prevent seizures ... multiple sclerosis (MS), according to a study released today that ... Annual Meeting in Washington, DC , April ... people with MS experience at some point in their life ... carrying vision from the eye to the brain gets inflamed," ...
(Date:4/16/2015)...  Amgen (NASDAQ: AMGN ) today announced that ... Tuesday, April 21, 2015, after the close of the ... a conference call with the investment community at 2 ... be Robert A. Bradway , chairman and chief ... team. Live audio of the conference call ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
Breaking Medicine Technology:Epilepsy Drug May Preserve Eyesight for People with MS 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2Diplomat Names Shannon M. Beltrand as New CISO 2
... TEMECULA, Calif., Nov. 17 Patient Safety Technologies, Inc. ... results. , "We are continuing to see strong year ... margins," stated Steven H. Kane, Chief Executive Officer of ... sales of safety sponges were comparable with revenues in ...
... WebMD Health Corp. (Nasdaq: WBMD ) today announced that executives ... Research Small and Mid Cap Conference on Friday, November 20, 2009 ... general public are invited to listen to a live audio broadcast ... accessed at www.wbmd.com (in the Investor Relations ...
Cached Medicine Technology:Patient Safety Technologies Reports Third Quarter Results 2Patient Safety Technologies Reports Third Quarter Results 3Patient Safety Technologies Reports Third Quarter Results 4Patient Safety Technologies Reports Third Quarter Results 5Patient Safety Technologies Reports Third Quarter Results 6
(Date:4/17/2015)... Washington, DC (PRWEB) April 17, 2015 ... the HHT Diagnoses and Treatment Act HR 1849 in ... improve diagnosis rates and treatment for patients with the ... introduced in the past, would be the first to ... diagnoses and appropriate treatment of hereditary hemorrhagic telangiectasia. This ...
(Date:4/17/2015)... As a board-certified orthopedic surgeon, Dr. ... of platelet-rich plasma (PRP) and stem cell ... known for its world-class care of injury-caused and chronic ... lacking in many other physicians offering regenerative medicines. ... for pain management and rehabilitation. Dr. Meier and MOSM ...
(Date:4/17/2015)... Tallahassee, Fla. (PRWEB) April 17, 2015 ... percent of dental restoration units are made overseas by ... Commission. Additionally, domestic labs remain unregulated in more than ... , The National Association of Dental Laboratories ... campaign to raise awareness among patients about the consequences ...
(Date:4/17/2015)... Jacksonville, Fla. (PRWEB) April 17, 2015 ... Cancer Center have signed a partnership agreement designed to ... , The institutions have agreed to create a ... Anderson’s treatment protocols and translational research. Baptist MD Anderson ... of 2015, providing a single destination for highly coordinated, ...
(Date:4/17/2015)... April 17, 2015 Scientists from ... multicenter team of U.S. and Venezuelan researchers, have ... in humans among an isolated tribe of Yanomami ... Bacterial diversity in the Yanomami, previously unexposed to ... nearly double that of people living in industrialized ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... Fat Pad Restoration on The Balancing Act on Lifetime TelevisionBOCA ... great doing it" is more than a tag line for ... is a leading expert and innovator in the science of ... a woman, she understands the emotional needs that many women ...
... Pharmakon introduced next generation of health ... quality natural liquid calcium & mineral supplement ... segments of athletes, women in pre and ... calcium supplementation. The innovative products of Aim ...
... the HR outsourcing marketplace, Empyrean Benefit Solutions is changing the status ... lower price. , ... Houston, TX (PRWEB) January 12, ... to grow by over 800% in annual revenue in their first ...
... employ comparative effectiveness research tools to address large, unwarranted variations ... benefits corporate spending. , ... Phoenixville, ... effectiveness data addresses large and unwarranted variations in corporate spending. ...
... SAN FRANCISCO, Jan. 12 Hiemstra Product Development, ... the debut of,hiQual, its proprietary electronic quality management ... the integration of hiQual, Hiemstra,s development team can ... the necessary documentation,required under ISO 13485:2003 and FDA ...
... Jan. 12 Acclarent, Inc., a leading,medical technology ... address conditions affecting the ear, nose and,throat, announced ... financing round.,Acclarent intends to use the proceeds to ... as on-going investment in product,development and clinical studies. ...
Cached Medicine News:Health News:Kay Renz Steps into PR Position for Cosmetic Foot, Leg and Vein Doctor, Jodi Schoenhaus 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 3Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 4Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 2Health News:Empyrean Benefit Solutions, Inc. Surpasses HRO Market's Expectations 3Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development 2Health News:Acclarent, Inc. Closes $26 Million Financing 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The Vibratome Roto-Shake Genie is an ... It performs five different mixing ... and rotating/rolling, as well as a ... The precision-engineered moving portion of the ...
... The Vibratome Roto-Shake Genie is ... platform. It performs five different ... rolling/rocking and rotating/rolling, as well as ... The precision-engineered moving portion of ...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Medicine Products: